52 Week Range
As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
FTSE Russell Says Vectura Group To Be Deleted From FTSE 250 After PMI Deal
Philip Morris Announces Satisfaction Of Japanese Antitrust Condition For Vectura Deal
Carlyle Waives Deadline For Timing Of Court Meeting, Vectura GM
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.
Biotechnology & Drugs
Unit 1, Prospect West, Bumpers Way
Bruno F. J. Angelici
Non-Executive Chairman of the Board
Chief Executive Officer, Executive Director
Paul Andrew Fry
Chief Financial Officer, Executive Director
Chief Scientific Officer and Executive Vice President – Product Development
Executive Vice President - Human Resources
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Cigarette maker Philip Morris won the support of Vectura for its 1.1 billion pound ($1.5 billion) takeover offer for the inhaled treatments maker after outbidding private equity firm Carlyle, the British company said on Thursday.
The takeover battle for British drugmaker Vectura Group will not go to auction on Wednesday after private equity firm Carlyle declared its 958 million pounds ($1.33 billion) bid as final before the deadline. ($1 = 0.7224 pounds) (Reporting by Yadarisa Shabong in Bengaluru)
British Business Minister Kwasi Kwarteng has asked officials to monitor drugmaker Vectura Group PLC's proposed takeover by U.S. tobacco group Philip Morris International Inc, the Times newspaper reported https://bit.ly/3efO4ag.
Tobacco group Philip Morris International agreed on Friday to buy Vectura for 1.05 billions pounds ($1.44 billion), giving the U.S. firm access to the British drugmaker's respiratory ailment treatments and inhaling device technology.
Cigarette maker Philip Morris International Inc said on Friday it will buy Vectura Group in a deal valuing the British pharmaceutical company at 1.05 billion pounds ($1.44 billion).
London's FTSE 250 index edged higher on Wednesday, boosted by Marks & Spencer and Softcat Plc following positive earnings updates, while Vectura Group topped the mid-cap index after agreeing a takeover by The Carlyle Group.
Vectura Group, a British pharmaceutical company focused on inhaled medicines, said on Wednesday it had agreed a 958 million pound ($1.36 billion) takeover by global investment firm The Carlyle Group.
GlaxoSmithKline PLC has lost an appeal seeking to overturn an $89.7 million verdict a jury handed down after finding that the company's Ellipta line of inhalers infringed a patent belonging to rival drug company Vectura Ltd.
* VECTURA GROUP PLC - ENERZAIR® BREEZHALER® RECEIVES REGULATORY APPROVAL
* VECTURA GROUP PLC - SIGNING OF A GLOBAL LICENCE AND DEVELOPMENT AGREEMENT WITH AERAMI THERAPEUTICS
* VECTURA GROUP PLC - AGM TRADING UPDATE & REITERATION OF 2020 GUIDANCE
* FINAL DECISION FROM EUROPEAN COMMISSION FOR GRANT OF MARKETING AUTHORISATION EXPECTED BE RECEIVED ABOUT 2 MONTHS AFTER CHMP OPINION
* VECTURA GROUP PLC - AT THIS TIME, VECTURA HAS NOT SEEN ANY IMPACT TO ITS BUSINESS FROM COVID-19
* VECTURA HAS NOT SEEN ANY IMPACT TO ITS BUSINESS FROM THE CORONAVIRUS OUTBREAK
* DGAP-ADHOC: SIXT SE: SIXT SE PUBLISHES OUTLOOK FOR FINANCIAL YEAR 2020 - MANAGING BOARD RESOLVES PROPOSAL TO SUSPEND DIVIDEND PAYMENT AND TO IMPLEMENT FURTHER MEASURES TO LIMIT THE FINANCIAL IMPACT OF THE CORONA CRISIS
Vectura Group said on Friday a British court had ruled in its favor on the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.
Vectura Group said on Friday a British court had ruled in its and partner Sandoz's favour over the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.
British drugmaker Vectura Group Plc's chief executive officer James Ward-Lilley will step down at the end of this month, the company said on Monday, saying it had agreed with the industry veteran that a change of leadership was needed.
British drugmaker Vectura Group Plc's chief executive officer, James Ward-Lilley, will step down by the end of this month, the company said on Monday.
* WILL RECEIVE A $2.5MILLION MILESTONE PAYMENT UNDER AN EXCLUSIVE LICENCE AGREEMENT WITH NOVARTIS AG Source text for Eikon: Further company coverage:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.